Gilead’s twice-yearly shot prevents 100% of HIV cases in trial with women
Gilead’s share price jumped by 5.7% following the announcement that its Phase III trial of lenacapavir met its primary endpoint.
21 June 2024
21 June 2024
Gilead’s share price jumped by 5.7% following the announcement that its Phase III trial of lenacapavir met its primary endpoint.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.